Epidemiological Characteristics of Chronic Viral Hepatitis in Kazakhstan: Data from Unified Nationwide Electronic Healthcare System 2014–2019

References

• Easterbrook P, Luhmann N, Newman M, et al. New WHO guidance for country validation of viral hepatitis B and C elimination. Lancet Gastroenterol Hepatol. 2021;6(10):778–780. doi:10.1016/S2468-1253(21)00267-3
   Web of Science ®Google Scholar
• World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030. World Health Organization; 2021.
   Google Scholar
• Cox AL, El-Sayed MH, Kao J-H, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533–542. doi:10.1038/s41575-020-0332-6
   PubMed Web of Science ®Google Scholar
• Papatheodoridi M, Papatheodoridis GV. Current status of hepatitis delta. Curr Opin Pharmacol. 2021;58:62–67. doi:10.1016/j.coph.2021.03.008
   Web of Science ®Google Scholar
• Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2019;221(10):1677–1687. doi:10.1093/infdis/jiz633
   Web of Science ®Google Scholar
• Hou C, Hua Z, Xu P, et al. Estimating the prevalence of hepatitis B by wastewater-based epidemiology in 19 cities in China. Sci Total Environ. 2020;740:139696. doi:10.1016/j.scitotenv.2020.139696
   Web of Science ®Google Scholar
• Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an update of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–7840. doi:10.3748/wjg.v22.i34.7824
   PubMed Web of Science ®Google Scholar
• World Health Organization. New report highlights global progress on reducing HIV, viral hepatitis and sexually transmitted infections and signals need for renewed efforts to reach 2030 targets. Geneva; 2021. Available from: https://www.who.int/news/item/20-05-2021-new-report-highlights-global-progress-on-reducing-hiv-viral-hepatitis-and-sexually-transmitted-infections-and-signals-need-for-renewed-efforts-to-reach-2030-targets. Accessed June 23, 2022.
   Google Scholar
• CDC WONDER Online Database, r.i., Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999–2018 on CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999–2018, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. 2020.
   Google Scholar
• Katsaga A, Kulzhanov M, Karanikolos M, et al. Kazakhstan health system review. Health Syst Transit. 2012;14(4):1–154.
   PubMedGoogle Scholar
• Igissinov N, Kulmirzayeva D, Sibinga CTS, et al. Epidemiological aspects of hepatitis B and C markers in blood donors in Kazakhstan; 2000–2011. Iran J Public Health. 2014;43(2):156–161.
   Web of Science ®Google Scholar
• Amerzhanov D, Suleimenova I, Davlidova S, et al. HBV prevention and treatment in countries of Central Asia and the Caucasus. Viruses. 2020;12(10):1112. doi:10.3390/v12101112
   Web of Science ®Google Scholar
• Davlidova S, Haley-Johnson Z, Nyhan K, et al. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: a systematic review. Int J Infect Dis. 2021;104:510–525. doi:10.1016/j.ijid.2020.12.068
   Web of Science ®Google Scholar
• Konysbekova A. Chronic viral hepatitis D – the current state of a problem. J Clin Med Kazakh. 2017;1(43):11–14. doi:10.23950/1812-2892-JCMK-00388
   Google Scholar
• Mukhatayeva A, Mustafa A, Dzissyuk N, et al. Author correction: hepatitis B, hepatitis C, tuberculosis and sexually-transmitted infections among HIV positive patients in Kazakhstan. Sci Rep. 2021;11(1):18123. doi:10.1038/s41598-021-97673-x
   Web of Science ®Google Scholar
• Almadiyeva A, Ibrayev S, Turgambayeva A, et al. Cost-effectiveness of oral protease inhibitors co-administration versus pegylated interferon-Alpha2b and ribavirin only for the patients with hepatitis C genotype 1 in Kazakhstan Health Care Settings. Iran J Public Health. 2018;47(12):1845–1853.
   Web of Science ®Google Scholar
• Yesmembetov K, Ashimkhanova A, Kaliaskarova K. First case in Kazakhstan of successful therapy with 2 consecutive direct-acting antiviral regimens in a patient with hepatitis C virus-induced decompensated liver cirrhosis on a liver transplant wait list. Exp Clin Transplant. 2016;14(Suppl 3):112–113.
   Google Scholar
• Baimakhanov Z, Kaniev S, Doskhanov M, et al. Evolution of liver transplantation in Kazakhstan: two-era experience of a single center, the first report. Transplant Proc. 2019;51(10):3360–3363. doi:10.1016/j.transproceed.2019.07.023
   Web of Science ®Google Scholar
• Sultanaliev T, Zhexembayev A, Mukazhanov A, et al. Liver transplant outcomes in a newly started program. Exp Clin Transplant. 2015;13(Suppl 3):120–122. doi:10.6002/ect.tdtd2015.P66
   Web of Science ®Google Scholar
• Saparbay J, Spatayev J, Sharmenov A, et al. Liver transplantation: a 10-year low-volume transplant center experience in Kazakhstan. Ann Transplant. 2021;26:e931786. doi:10.12659/AOT.931786
   Web of Science ®Google Scholar
• Agency, B.o.N.s.O.t. Taldau statistical database. 2014–2019. 2019.
   Google Scholar
• POvkovskiy VI. Viral Hepatitis in Russian Federation 2018.
   Google Scholar
• Beutels P, Musabaev EI, Van Damme P, et al. The disease burden of hepatitis B in Uzbekistan. J Infect. 2000;40(3):234–241. doi:10.1053/jinf.1998.0666
   Web of Science ®Google Scholar
• WHO. WHO progress report on access to hepatitis C treatment. 2018.
   Google Scholar
• Chen HY, Shen D-T, Ji D-Z, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512–521. doi:10.1136/gutjnl-2018-316601
   PubMed Web of Science ®Google Scholar
• Bockmann J-H, Grube M, Hamed V, et al. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort. BMC Gastroenterol. 2020;20(1):24. doi:10.1186/s12876-020-1168-9
   Web of Science ®Google Scholar
• Ochner M, Wong L, Wimmer-Kunitomo K. Hepatocellular cancer: risk factors and survival in Pacific Islanders compared to Caucasians in Hawaii. Ethn Dis. 2010;20:169–173.
   Web of Science ®Google Scholar
• Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–1638. doi:10.1053/j.gastro.2009.01.052
   PubMed Web of Science ®Google Scholar
• Stroffolini T, Rapicetta M, Di Stefano R. Hepatitis C virus clearance and gender. Gut. 2007;56(6):884.
   Web of Science ®Google Scholar
• ECDC. Epidemiological Assessment of Hepatitis B and C Among Migrants in the EU/EEA. Stockholm: ECDC; 2016.
   Google Scholar